Clinical Observations, For The Treatment Of Chronic Obstructive Pulmonary Disease Pulmonary Arterial Hypertension (phlegm Lung Lung Inflation). Yifei Ii

ObjectiveTo observe the therapeutic effect and mechanism of action of Yi Fei No. II on pulmonary artery hypertension (PAH) in patients with chronic obstructive pulmonary disease (COPD) .To provide scientific basis for clinical treatment. MethodsFifty-two COPD patients complicated by PAH were randomly divided into two groups including twenty-six patients in therapy group and the other twenty-six patients in control group. Patients in therapy group were treated with Yi Fei No. II (100ml, p.o., three times ervery day)on the base of conventional therapy and patients in control group were treated only with conventional therapy. Course of treatment in both groups were 14 days. It was designed to investigate the changes of clinical symptoms, physical signs, hemodynamics, the function of right heart, arterial blood gas analysis and pulmonary function. Results1 The total effective rates of therapy group and control group were 92.31% and 26.92 % respectively.The difference between two groups was statistical significant (P<0.01) .The therapeutic effect of therapy group surpassed that of control group.2 The improvement of clinical symptoms and physical signs in therapy group, especially of pant, dyspnea and stethocatharsis, was better than that in control group. The difference between two groups were statistical significant (P<0.05or P<0.01).3 In therapy group, the levels of mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistant (PVR) were obviously reduced (P<0.01orP<0.001), while the levels of mean systemic circulation arterial pressure (mSAP), heart rate(HR) and cardiac output (CO) was invariably (P>0.05 ).4 In therapy group, the levels of Q-B interval, Q-B/B-Yand Q-BI were obviously reduced (P<0.0lorP<0.00l).The levels of B-Y interval, B-YI, time and HS were obviously increased (P < 0.01 orP<0.001). In other words, the function of right heart was obviously improved in therapy group.5 In therapy group, the levels of forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1% and PaO2 were obviously increased, and the degree of increase in therapy group was higher than that in control group(y<0.05). ConclusionFor COPD patients complicated by PAH, Yi Fei No. II can improve the clinical symptoms, physical signs , the function of lung and right heart, reduce the levels of mPAP, PVR and increase the levels of PaO2. But it can't influence the levels of mSAP, HR and CO. In other words, Yi Fei No. II is an effective drug.